AU2018372396A1 - Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient - Google Patents

Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient Download PDF

Info

Publication number
AU2018372396A1
AU2018372396A1 AU2018372396A AU2018372396A AU2018372396A1 AU 2018372396 A1 AU2018372396 A1 AU 2018372396A1 AU 2018372396 A AU2018372396 A AU 2018372396A AU 2018372396 A AU2018372396 A AU 2018372396A AU 2018372396 A1 AU2018372396 A1 AU 2018372396A1
Authority
AU
Australia
Prior art keywords
composition
thymosin beta
mucin
goblet cell
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018372396A
Other languages
English (en)
Inventor
Sinwook KANG
Kyoungsun Kim
Jihye SUNG
Wonsuk YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HLB Therapeutics Co Ltd
Original Assignee
HLB Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HLB Therapeutics Co Ltd filed Critical HLB Therapeutics Co Ltd
Publication of AU2018372396A1 publication Critical patent/AU2018372396A1/en
Assigned to HLB Therapeutics Co., Ltd. reassignment HLB Therapeutics Co., Ltd. Amend patent request/document other than specification (104) Assignors: G-TREEBNT CO., LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2018372396A 2017-11-24 2018-11-23 Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient Abandoned AU2018372396A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762590444P 2017-11-24 2017-11-24
US62/590,444 2017-11-24
PCT/KR2018/014522 WO2019103523A2 (ko) 2017-11-24 2018-11-23 티모신 베타 4 또는 이의 유도체를 유효성분으로 포함하는 술잔세포 증식 또는 뮤신 분비 촉진용 조성물

Publications (1)

Publication Number Publication Date
AU2018372396A1 true AU2018372396A1 (en) 2020-06-25

Family

ID=66630753

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018372396A Abandoned AU2018372396A1 (en) 2017-11-24 2018-11-23 Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient

Country Status (8)

Country Link
US (1) US20200353052A1 (enExample)
EP (1) EP3715451A4 (enExample)
JP (1) JP2021504349A (enExample)
KR (1) KR20200081402A (enExample)
CN (1) CN111386337A (enExample)
AU (1) AU2018372396A1 (enExample)
CA (1) CA3083101A1 (enExample)
WO (1) WO2019103523A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023027B (zh) * 2020-07-21 2023-03-14 广东海洋大学 胸腺素或其衍生物的应用和治疗快感缺乏型抑郁症的药物
CN111888463B (zh) * 2020-08-18 2021-09-21 华中农业大学 用于治疗抑郁症的胸腺素β4药物制剂与制备方法及其应用
WO2024233903A1 (en) * 2023-05-11 2024-11-14 Wayne State University Combination treatments to promote epithelial integrity and treat ocular disorders
KR20250098014A (ko) * 2023-12-21 2025-07-01 주식회사 비제이와이 탈모 예방 또는 발모 촉진용 흉선 유래 펩타이드 유도체 및 이의 이용

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US20110020449A1 (en) * 1998-07-30 2011-01-27 Regenerx Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivatives
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
WO2003086449A1 (en) * 2002-04-12 2003-10-23 Yale University ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN β 4
US20090131313A1 (en) * 2005-06-17 2009-05-21 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods for treating or preventing tissue deterioration, injury or damage
CN1896096A (zh) * 2005-07-15 2007-01-17 北京诺思兰德生物技术有限责任公司 基因工程方法生产的高活性胸腺素β4衍生物
CN100484957C (zh) * 2005-09-23 2009-05-06 北京诺思兰德生物技术股份有限公司 胸腺素β4衍生物及其应用
WO2009033814A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
US9504730B2 (en) * 2010-09-30 2016-11-29 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
KR20160047321A (ko) * 2014-10-22 2016-05-02 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 조성물
JP6634451B2 (ja) * 2014-10-22 2020-01-22 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４を含有する組成物、およびそれを含む医薬製剤
CN106692949B (zh) * 2016-12-23 2022-03-15 北京诺思兰德生物技术股份有限公司 一种用于治疗眼部疾病的药物及其组合物
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제

Also Published As

Publication number Publication date
CA3083101A1 (en) 2019-05-31
EP3715451A2 (en) 2020-09-30
KR20200081402A (ko) 2020-07-07
WO2019103523A2 (ko) 2019-05-31
WO2019103523A3 (ko) 2019-07-18
EP3715451A4 (en) 2021-07-21
US20200353052A1 (en) 2020-11-12
JP2021504349A (ja) 2021-02-15
CN111386337A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
US20120315256A1 (en) Use of transforming growth factor - beta 1 (tgf-b1) inhibitor peptides for the treatment of corneal fibrosis and/or haze
EP2664337B1 (en) Amniotic membrane preparations and purified compositions and methods of use
KR102496934B1 (ko) 안과용 제제
US20200353052A1 (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
CN1315531C (zh) 用于眼睛干燥及与眼睛干燥相关的疾病的治疗剂
KR20080031195A (ko) 각결막 질환의 예방 또는 치료제
JP2020530435A (ja) Ｇｌｙ−Ｔβ４（Ｇｌｙ−チモシンβ４）を含有する眼球乾燥症の治療用薬学的組成物
EP3338792B1 (en) Corneal damage prevention/treatment composition comprising thymosin beta 4 and citric acid as active ingredients
CN101537172A (zh) 一种含有重组人角质细胞生长因子-2滴眼液及其制备方法
HK40023769A (en) Composition for promoting goblet cell proliferation or mucin secretion comprising thymosin beta 4 or derivative thereof as active ingredient
EP3827814A1 (en) Ophthalmic formulations
KR102790252B1 (ko) 각막 손상 또는 안구건조증 예방 또는 치료용 조성물
JP4778515B2 (ja) 角膜疾患治療剤
JP2006306757A (ja) 角膜疾患治療剤
KR20170021667A (ko) 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
HK40053198A (en) Ophthalmic formulations
CN115779072A (zh) 一种包含低浓度il-2的用于治疗干眼的药物组合物
HK1241379B (zh) 短合成肽及其治疗和/或预防乾眼症的用途
HK1258026A1 (en) A hepatocyte growth factor receptor (hgfr)-binding composition for use in a method of treating corneal haze or scarring
JP2007063218A (ja) 角膜疾患治療剤
HK1213499B (zh) 羊膜製品和純化的組合物及其使用方法

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HLB THERAPEUTICS CO., LTD.

Free format text: FORMER NAME(S): G-TREEBNT CO., LTD.

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period